A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
Status:
Recruiting
Trial end date:
2024-04-09
Target enrollment:
Participant gender:
Summary
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced
or metastatic urinary tumors and other solid tumors will be investigated to determine the
dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1.
In phase Ib study, the safety and tolerability of BL-B01D1 at the phase Ia recommended dose
will be further investigated, and recommended phase II dose (RP2D) for phase II clinical
studies will be determined.
In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of
BL-B01D1 in patients with locally advanced or metastatic urinary tumors and other solid
tumors will be evaluated.